2.97

0.00% 0.00

After Hours: 2.99 0.02 +0.67%

Prime Medicine Inc (PRME)

Overview News Price History Option Chain Financials Discussions Forecast

Prime Medicine Inc stock is traded at $2.97, with a volume of 2.33M. It is up +0.00% in the last 24 hours and down -19.73% over the past month. Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Previous Close:

$2.97

Open:

$3.01

24h Volume:

2.33M

Relative Volume:

0.93

Market Cap:

$536.43M

Revenue:

$4.63M

Net Income/Loss:

$-201.14M

P/E Ratio:

-2.1614

EPS:

-1.3741

Net Cash Flow:

$-167.10M

1W Performance:

+10.00%

1M Performance:

-19.73%

6M Performance:

-19.95%

1Y Performance:

+130.23%

1-Day Range:

$2.89

$3.05

1-Week Range:

$2.70

$3.0999

52-Week Range:

$1.18

$6.94

Prime Medicine Inc Stock (PRME) Company Profile

Name

Prime Medicine Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617-465-0013

Address

60 FIRST ST., CAMBRIDGE

Employee

146

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

PRME's Discussions on Twitter

Compare PRME vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRME Prime Medicine Inc	2.97	536.43M	4.63M	-201.14M	-167.10M	-1.3741
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Initiated	Oppenheimer	Outperform
May-27-25	Downgrade	Citigroup	Buy → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform
May-20-24	Initiated	H.C. Wainwright	Buy
May-16-24	Upgrade	Citigroup	Neutral → Buy
Apr-22-24	Initiated	Chardan Capital Markets	Buy
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform
Jan-16-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Initiated	Citigroup	Neutral
Oct-09-23	Initiated	BMO Capital Markets	Outperform
Jul-31-23	Initiated	Guggenheim	Buy
Apr-18-23	Initiated	Stifel	Buy
Nov-14-22	Initiated	Goldman	Neutral
Nov-14-22	Initiated	JP Morgan	Overweight
Nov-14-22	Initiated	Jefferies	Buy
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight

View All

Prime Medicine Inc Stock (PRME) Latest News

May 23, 2026

PRME Q1 2026 Earnings: EPS Worse Than Expected as Pre-Revenue Biotech Advances PipelinePro Level Trade Signals - Newser

May 23, 2026

May 22, 2026

PRME Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Consistency Score - Newser

May 22, 2026

May 19, 2026

Prime Medicine (PRME) Q1 2026 Disappoints — EPS $-0.28 Below $-0.26 ViewsEarnings Turnaround - Newser

May 19, 2026

Oppenheimer Maintains Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $11 - Moomoo

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026